- Home
- SUPN vs UAA Comparison
SUPN vs UAA Comparison
Compare SUPN & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- UAA
- Stock Information
- Founded
- SUPN 2005
- UAA 1996
- Country
- SUPN United States
- UAA United States
- Employees
- SUPN N/A
- UAA N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- UAA Apparel
- Sector
- SUPN Health Care
- UAA Consumer Discretionary
- Exchange
- SUPN Nasdaq
- UAA Nasdaq
- Market Cap
- SUPN 2.6B
- UAA 2.2B
- IPO Year
- SUPN 2012
- UAA N/A
- Fundamental
- Price
- SUPN $44.80
- UAA $4.86
- Analyst Decision
- SUPN Buy
- UAA Hold
- Analyst Count
- SUPN 2
- UAA 20
- Target Price
- SUPN $43.00
- UAA $6.91
- AVG Volume (30 Days)
- SUPN 654.2K
- UAA 12.1M
- Earning Date
- SUPN 11-03-2025
- UAA 11-06-2025
- Dividend Yield
- SUPN N/A
- UAA N/A
- EPS Growth
- SUPN 1411.53
- UAA N/A
- EPS
- SUPN 1.14
- UAA 0.23
- Revenue
- SUPN $665,125,000.00
- UAA $5,114,713,000.00
- Revenue This Year
- SUPN $4.84
- UAA N/A
- Revenue Next Year
- SUPN $17.69
- UAA $2.56
- P/E Ratio
- SUPN $38.93
- UAA $21.45
- Revenue Growth
- SUPN 5.55
- UAA N/A
- 52 Week Low
- SUPN $29.16
- UAA $4.76
- 52 Week High
- SUPN $46.79
- UAA $11.89
- Technical
- Relative Strength Index (RSI)
- SUPN 58.16
- UAA 32.72
- Support Level
- SUPN $43.44
- UAA $4.76
- Resistance Level
- SUPN $46.72
- UAA $5.05
- Average True Range (ATR)
- SUPN 1.08
- UAA 0.15
- MACD
- SUPN -0.48
- UAA 0.04
- Stochastic Oscillator
- SUPN 40.60
- UAA 18.18
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.